No Abstract Assistant Managing EditorWith buzz growing about Micromet Inc.'s BiTE antibody blinatumomab (MT103) ahead of the upcoming American Society of Hematology meeting, the Bethesda, Md.-based firm scored an early stage deal with Sanofi-Aventis SA to develop another BiTE compound.
With buzz growing about Micromet Inc.'s BiTE antibody blinatumomab (MT103) ahead of the upcoming American Society of Hematology meeting, the Bethesda, Md.-based firm scored an early stage deal with Sanofi-Aventis SA to develop another BiTE compound. (BioWorld Today)
PDL BioPharma Inc., which promised significant returns to shareholders since adopting an unusual royalty-collecting business model following last year's spinoff of its R&D division, has opted to monetize a percentage of its antibody royalties from Genentech Inc. products to return a special cash dividend by year-end. (BioWorld Today)
When Medivation Inc. gained clearance in March to start its Phase III trial of MDV3100 in prostate cancer, a company executive told BioWorld Today the firm would consider partnering the drug if the right opportunity came along - as it had for Alzheimer's disease drug Dimebon, which scored a potential $725 million deal with Pfizer Inc. last year. (BioWorld Today)
Investors - and prospective partners - hoping that detailed data emerging from this year's Obesity Society meeting in Washington might shed more light on the three frontrunners in the weight loss drug race came away with some more promising data on each but no clear winner. (BioWorld Today)
Shares of Biogen Idec Inc. and partner Dublin, Ireland-based Elan Corp. plc took a hit Friday after news of a European review disclosed a higher number of PML cases linked to multiple sclerosis drug Tysabri (natalizumab) than previously reported. (BioWorld Today)
